Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1999-01-06
2000-10-03
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514561, 514563, 514646, 514656, 514676, 514679, 514685, 514365, 514369, 514370, 514372, 514374, 514376, 514377, 514378, 514388, 514461, 514451, A61K 3119, A61K 31195, A61K 31135, A61K 3112, A61K 31425
Patent
active
061274224
DESCRIPTION:
BRIEF SUMMARY
Influenza viruses cause an infectious disease for which there is no adequate therapeutic agent. The disadvantages of existing treatments include the onset of clinical resistance within thirty six hours and the ineffectiveness of the agents against influenza B. Killed influenza virus vaccines have been available for over sixty years. However, these vaccines have not lessened the morbidity, mortality or severe financial loss caused by this disease. It follows that an agent which treats or prevents an influenza infection or is effective at preventing the clinical symptoms associated with an influenza infection will result in a significant benefit to society.
Currently, the only compounds approved for the therapeutic and prophylactic treatment of influenza infections are the adamantanes: amantadine and rimantadine. These compounds inhibit influenza A by inhibiting the function of the M2 ion channel activity of the virus. Amantadine is a potent in vitro inhibitor of influenza A virus as demonstrated by standard antiviral assays such as the plaque reduction assay. Amantadine is effective in reducing the duration of fever and other systemic complaints including but not limited to myalgia (muscular ache) and fatigue when administered to individuals infected with influenza A within forty-eight hours of the onset of clinical symptoms. It has also been observed that amantadine results in a one hundred-fold decrease of virus titer in the nasal washes of human volunteers infected with wild-type influenza virus which correlates with a dramatic decrease in fever score. Thus, in vitro influenza inhibition is predictive of useful in vivo effects, i.e. a reduction of the clinical symptoms associated with the influenza infection.
The present invention derives from the fact that influenza is an enveloped virus which dictates that the virus envelope must be fused with the endosomal membrane of the host cell in order to initiate the process of introducing its genetic information into the cell. Because this process is common to all enveloped viruses, it is an attractive target for antiviral chemotherapy. Examples of envelope viruses which are inhibited according to the present invention include influenza, bovine diarrheal, hepatitis C, tick borne encephalitis and the like. The fusion domain of the envelope glycoprotein of influenza, hemagglutinin (HA) has been well characterized. See, White J. M., Annu. Rev. Physiol. vol. 52, pages 675-697 (1990) which is herein incorporated by reference.
Influenza virus HA provides at least two distinct functions: 1) recognition of the host cell receptor, i.e., sialic acid residues on glycoconjugates, and 2) fusion of the viral envelope with the endosomal membrane. Both functions are essential for the propagation of influenza virus in vitro and in vivo. During viral maturation, monomeric HA is inserted into a lipid bilayer, post-translationally modified and oligomerized into a trimer of identical subunits (trimeric HA). The infectivity of the progeny virus is contingent upon a site-specific cleavage of HA by host cell protease(s). This cleavage results in the formation of two polypeptide chains, HA1 and HA2, which remain associated by non-covalent interactions as well as by an intermolecular and intramolecular disulfide bonds.
It has been established that influenza HA has two functionally relevant conformations. One conformation (Form A) exists as a metastable structure at neutral pH and mediates receptor recognition. Following receptor mediated binding to the host cell, the virus is transported to the endosomal compartment where it encounters an acidic environment. The low pH triggers a dramatic structural rearrangement of HA (Form A) which results in the formation of the other, more stable conformation of HA (Form B).
Form B of HA is required for fusion of the virus envelope with the endosomal membrane. It is the structural rearrangement from Form A to Form B of HA that allows the fusion domain of HA to directly interact with the endosomal membrane enabling the release of viral genetic inform
REFERENCES:
patent: 2703809 (1955-03-01), Ritchie
patent: 2744100 (1956-05-01), Subluskey
patent: 2744102 (1956-05-01), Subluskey
patent: 2750382 (1956-12-01), Bible et al.
patent: 2750405 (1956-06-01), Ritchie et al.
patent: 2750407 (1956-06-01), Ritchie
patent: 2753357 (1956-07-01), Bible, et al.
patent: 2759014 (1956-08-01), Bible
patent: 2767162 (1956-10-01), Picha
patent: 2854474 (1958-09-01), Bible
patent: 2862955 (1958-12-01), Hoehn
patent: 2947778 (1960-08-01), Bible
patent: 3014957 (1961-12-01), Hoehn
patent: 3038930 (1962-06-01), Bible
patent: 3668223 (1972-06-01), Jones
patent: 4252804 (1981-02-01), Joullie et al.
patent: 4333941 (1982-06-01), Baratz et al.
patent: 5015644 (1991-05-01), Roth et al.
patent: 5276053 (1994-01-01), Johnson
patent: 5321044 (1994-06-01), Peters et al.
UEDA, et al.: "The Leaf Oil and Resin Acid Components of Lacebark Pine, Pinus bungeana Zucc." Tottori Daigaku Kogakubu Kenkyu Hokiku, vol. 20, No. 1, 1989 Japan, pp. 87-96.
Turner, et al., J. Chem. Soc. C., 1971, vol. 3, 547-553.
Cambie, et al., Aust. J. Chem., 1974, vol. 27, No. 9, 2001-2016.
Tahara, et al., Chem. Pharm. Bull., 1976, vol. 24, No. 7, 1497-1501.
Standley, et al., J. Atmos. Chem., 1994, vol. 18, No. 1, 1-15.
Matsumoto, et al., Chem. Pharm. Bull., 1996, vol. 44, No. 3, 530-533.
Caplus Abstr., No. 99:212742, Burnell, et al., Can. J. Chem., 1983, vol. 61, No. 11, 2461-2465.
Burnell, et al., Synth. Commun., 1984, vol. 14, No. 13, 1229-1237.
Cambie, et al., Aust. J. Chem., 1990, vol. 43, No. 5, 883-893.
Matsumoto, et al., Chem. Pharm. Bull., 1993, vol. 41, No. 11, 1960-1964.
Chemical Abstracts, Abstract #2502; vol. 50, No. 4, Feb. 25, 1956, Michitoshi Ohta.
G. Defaye-Duchateau, "Oxydations dans la serie de l'acide dehydroabietique," 1964, Paris, 1469-1473.
Georges Dupont, et al., "Oxydation de l'acide abietique par l'acetate mercurique. Derives de l'acide dehydroabietique substitutes dans le cycle B," 1955, Paris, 708-715.
J. C. Sircar, et al., "Free-Radical Bromination of Methyl Abietate by N-Bromosuccinimide and Solvolysis of the Products,", vol. 35, No. 9, Sep., 1970, 3090-3093.
Chem. Abstr., vol. 112, No. 21, May 21, 1990, Abstract No. 198830, Sugai, et al.
Chem. Abstr., vol. 110, No. 9, Feb. 27, 1989, Abstract No. 75825, Nishi, et al.
Chem. Abstr., vol. 91, No. 23, Dec. 3, 1979, Abstract No. 193454, Pelletier, et al.
Chem. Abstr., vol. 81, No. 7, Aug. 19, 1974, Abstract No. 25842, Wirthlin, et al.
Chem. Abstr., vol. 121, No. 17, Oct. 24, 1994, Abstract No. 195010, Tagat, et al.
Chem. Abstr., vol. 120, No. 11, Mar. 14, 1994, Abstract No. 134850, Selwood, et al.
Chem. Abstr., vol. 61, No. 5, Aug. 31, 1964, Abstract No. 5699f, Tahara, et al.
Helvetica Chemica Acta., vol. 57, No. 2, Mar. 13, 1974, Basel Ch., 351-368.
Tetrahedron, vol. 21, No. 8, Aug. 1965, Oxford GB, 2133-2154.
Cruz Frederico G., et al., Phytochemistry, vol. 31, No. 8, 1992, pp. 2793-2796.
Chem. Abstr., vol. 110, No. 21, Nov. 20, 1989, Abstract No., 195166, Node, et al.
Chem. Abstr., vol. 88, No. 25, Jun. 19, 1978, Abstract No. 191065, Ichinohe.
Chem. Abstr., vol. 83, No. 11, Sep. 15, 1975, Abstract No. 97643, Ichinohe.
Chem. Abstr., vol. 81, No. 5, Aug. 5, 1974, Abstract No. 25842, Wirthlin, et al.
Database Crossfire, Beilstein Informationssysteme, GMBH. Frankfort DE, Beilstein registry No. 4824891, XP002060909, Richard C. Cambie, et al., Australian Journal of Chemistry, vol. 44, No. 11, 1991, pp. 1553-1573.
Database Crossfire, Beilstein Informationssysteme, GMBH. Frankfurt DE, Beilstein registry No. 2179057, XP002060813, Richard C. Cambie, et al., Australian Journal of Chemistry, vol. 27, 1974, pp. 2413-2419.
Database Crossfire, Beilstein Informationssysteme, GMBH. Frankfurt DE, Beilstein registry No. 2887142, XP002060814, Richard C. Cambie, et al., Australian Journal of Chemistry, vol. 25, 1972, pp. 974-980.
Database Crossfire, Beilstein Informationssysteme, GMBH. Frankfurt DE, Beilstein registry No. 2920097, XP002060815, Richard C. Cambie, et al., Australian Journal of Chemistry, vol. 27,
Colacino Joseph M.
Hornback William J.
Mauldin Scott C.
Munroe John E.
Tang Joseph C.
Eli Lilly and Company
Musser Arlene K.
Travers Russell
LandOfFree
Anti-viral method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-viral method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-viral method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-196412